SMS Pharmaceuticals posts Q1FY23 consolidated loss at Rs. 12.76 Cr

The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.

Vascular experts establish appropriate use of IVUS in peripheral interventions

Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions

Roche gets USFDA approval of Xofluza to treat influenza in children

Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease

Tetra Bio-Pharma secures $6,000,000 financing from Alpha Blue Ocean

Congenica announces partnership with Avesthagen

New deal strengthens Congenica’s presence in India

MoU signed between Ministry of Ayush and MeitY

MeitY will provide technical support for digitalisation of the Ayush Sector under the Ayush Grid project for a period of three years

We must be careful in adopting global technological practices, says Union Health Secretary

Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces

Hikal shows 17% degrowth in Q1 FY23

Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore

Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr

Apollo Hospital Group completed the acquisition of a hospital asset in Gurugram for a consideration of around Rs 450 crore.